Our study aimed to elucidate the comprehensive mutation profile of patients with MET amplification or METex14 skipping mutations in NSCLC receiving MET TKI therapy by analyzing molecular factors that could contribute to their prognosis. This evidence concerns the gene MET and non-small cell lung carcinoma.